抗血小板治疗与院外心脏骤停后患者结局的关联
本研究纳入2005年1月至2014年10月在一家学术医疗中心治疗的1054例院外心脏骤停患者,将前瞻性登记数据与结构化病历回顾结合,摘录居家抗血小板和抗凝药物使用情况。调整模型中,抗血小板药与较低的复苏后病情严重度(调整OR 0.50,95%CI 0.33-0.77)、更高的出院生存率(调整OR 1.74,95%CI 1.08-2.80)和更高的良好功能结局几率(调整OR 2.11,95%CI 1.17-3.79)相关;抗凝药与上述结局均无关联。作者认为,通过抗血小板药预防骤停期间和骤停后微血管血栓形成可能是一个改善院外心脏骤停后结局的新治疗靶点。
要点
- 在1054例院外心脏骤停患者中,295例(28%)骤停前处方抗血小板药,147例(14%)处方抗凝药。
- 调整模型中,抗血小板药与较低的复苏后病情严重度相关(调整OR 0.50,95%CI 0.33-0.77)。
- 调整模型中,抗血小板药与更高的出院生存率相关(调整OR 1.74,95%CI 1.08-2.80)。
- 调整模型中,抗血小板药与更高的良好功能结局几率相关(调整OR 2.11,95%CI 1.17-3.79)。
- 任何抗凝药均与病情严重度、出院生存率或良好功能结局无关联。
适用人群与场景
- 2005年1月至2014年10月在一家学术医疗中心治疗的院外心脏骤停患者。
研究设计与关键结果
- 研究类型为在单家学术医疗中心开展的前瞻性院外心脏骤停登记联合结构化病历回顾的关联分析,共纳入1054例患者。
- 295例(28%)骤停前处方抗血小板药,147例(14%)处方抗凝药。
- 调整模型中,抗血小板药与较低的复苏后病情严重度相关(调整OR 0.50,95%CI 0.33-0.77)。
- 调整模型中,抗血小板药与更高的出院生存率相关(调整OR 1.74,95%CI 1.08-2.80)。
- 调整模型中,抗血小板药与更高的良好功能结局几率相关(调整OR 2.11,95%CI 1.17-3.79)。
- 任何抗凝药均与病情严重度、出院生存率或良好功能结局无关联。
证据类型、等级与局限
- 证据类型:单中心前瞻性登记联合结构化病历回顾的观察性关联分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,通过抗血小板药预防骤停期间和骤停后微血管血栓形成可能是一个改善院外心脏骤停后结局的新治疗靶点。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Cessation of blood flow during out-of-hospital cardiac arrest (OHCA) results in microvascular thrombosis, protracted hypoperfusion after return of spontaneous circulation and damage to vital organs. We tested the hypothesis that pre-arrest antiplatelet and anticoagulant medication use would be associated with less post-arrest organ dysfunction and better outcomes.
METHODS: We included OHCA patients treated from January 2005 to October 2014 at a single academic medical center. We combined our prospective OHCA registry of clinical and demographic data with a structured chart review to abstract home antiplatelet and anticoagulant medications. We fit unadjusted and adjusted regression models to test the association of antiplatelet and anticoagulant medication use with early post-arrest illness severity, survival and functionally favorable recovery.
RESULTS: Of 1054 subjects, 295 (28%) were prescribed an antiplatelet agent and 147 (14%) were prescribed an anticoagulant prior to arrest. In adjusted models, antiplatelet agents were associated with lower post-arrest illness severity (adjusted OR 0.50 95% CI 0.33-0.77), greater odds of survival to discharge (adjusted OR 1.74 95% CI 1.08-2.80) and greater odds favorable functional outcome (adjusted OR 2.11 95% CI 1.17-3.79). By contrast, anticoagulation via any agent was not associated with illness severity, survival to discharge or favorable outcome.
CONCLUSION: Preventing intra-arrest and post-arrest microvascular thrombosis via antiplatelet agents could represent a novel therapeutic target to improve outcomes after OHCA.
参考来源
- Gianforcaro A, Kurz M, Guyette FX, et al. Association of antiplatelet therapy with patient outcomes after out-of-hospital cardiac arrest. Resuscitation. 2017. PMID: 29032299. doi:10.1016/j.resuscitation.2017.10.007
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。